WuXi AppTec Receives Gold Medal in 2024 EcoVadis Sustainability Rating
WuXi AppTec Receives Gold Medal in 2024 EcoVadis Sustainability Rating
SHANGHAI, Nov. 20, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that it has been awarded a gold medal in the 2024 EcoVadis business sustainability rating, ranking in the top 2% of all participating companies. This achievement reflects WuXi AppTec's commitment to sustainability and its ongoing efforts to integrate environmental and social responsibilities into the company's business strategies and operations.
2024年11月20日,上海/美通社/——藥明康德(WuXi AppTec)是一家全球公司,提供廣泛的研發和製造服務,爲藥品和生命科學行業的公司提供支持。該公司宣佈,在2024年EcoVadis企業可持續性評級中榮獲金牌,位列所有參與公司的頂部2%。這一成就反映了藥明康德致力於可持續發展的承諾,以及將環境和社會責任融入公司業務戰略和運營的不懈努力。
EcoVadis is a leading ratings organization in supply chain sustainability, serving as a crucial benchmark for companies of all sizes worldwide to enhance their long-term sustainability performance in business and value chains. WuXi AppTec's EcoVadis score of 80 out of 100 points reflects steady improvements in the four key ESG categories: environment, labor & human rights, ethics, and sustainable procurement.
EcoVadis是供應鏈可持續性的領先評級機構,是全球各大小公司的重要基準,以增強其長期可持續性在業務和價值鏈中的表現。藥明康德在EcoVadis評分中獲得80分,反映了在四個關鍵ESG類別(環境、勞工和人權、道德和可持續採購)中穩步改進。
"Receiving the EcoVadis Gold Medal is a reflection of the strong progress we have made implementing sustainable development and strong ESG practices throughout our entire value chain," said Edward Hu, Vice Chairman of WuXi AppTec and Chairman of WuXi AppTec's ESG Committee. "We remain dedicated to advancing sustainability efforts in every aspect of our operations. We are proud to support our customers in delivering innovative new therapies to patients and make a lasting, positive impact on the healthcare industry as a whole."
「獲得EcoVadis金牌是我們在整個價值鏈中實施可持續發展和堅定ESG實踐取得的顯著進展的體現,」藥明康德副董事長、藥明康德ESG委員會主席胡洪宣(Edward Hu)表示。「我們致力於推動在我們運營的各個方面進行可持續性努力。我們爲支持客戶交付創新新療法給患者並在整個醫療保健行業產生持久積極影響感到自豪。」
As an enabler of innovation, a trusted partner, and a contributor to the global pharmaceutical and life sciences industry, WuXi AppTec integrates ESG priorities in all aspects of its global business operations. In 2024, WuXi AppTec ranked #1 in the Global Life Sciences Tools & Services Industry in S&P Global's Corporate Sustainability Assessment and received an AA ESG rating from MSCI for the fourth consecutive year. The company was also named to the S&P Global Sustainability Yearbook and the FTSE4Good Index Series in both 2023 and 2024, and was recognized as an Industry and Regional "Top-Rated" company by Sustainalytics. WuXi AppTec's outstanding ESG performance has been widely acknowledged by major global ESG rating agencies, including CDP and ISS.
作爲創新推動者、值得信賴的合作伙伴,藥明康德將ESG優先事項融入其全球業務運營的各個方面。2024年,藥明康德在S&P Global公司可持續性評估中全球生命科學工具與服務行業中排名第一,並連續第四年獲得MSCI的AA ESG評級。該公司還連續在2023年和2024年被評爲S&P Global可持續年鑑和FTSE4Good指數系列成員,並被Sustainalytics評爲行業和區域「最佳」公司。藥明康德卓越的ESG表現受到主要全球ESG評級機構(包括CDP和ISS)的廣泛認可。
In addition, WuXi AppTec participates in global efforts to advance sustainability. For example, WuXi AppTec joined the United Nations Global Compact (UNGC) in 2024 to support its ten sustainability principles. In 2023, WuXi AppTec joined the Science Based Targets initiative (SBTi) to reduce carbon emissions.
此外,藥明康德參與全球推動可持續發展的努力。例如,藥明康德於2024年加入了聯合國全球契約(UNGC),以支持其十項可持續發展原則。2023年,藥明康德加入了科學基礎目標倡議(SBTi)以減少碳排放。
About WuXi AppTec
關於藥明康德
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development, and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024, and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."
作爲一家在全球貨幣,藥明康德在亞洲、歐洲和北美洲開展業務,提供廣泛的研發和製造業務,以促進全球藥品和生命科學行業的發現,併爲患者提供開創性的治療方案。通過其獨特的業務模式,藥明康德的一體化端到端服務包括化學藥品CRDMO(合同研究、開發和製造組織)、生物發現、臨床前測試和臨床研究服務、先進治療CTDMO(合同測試、開發和製造組織),幫助客戶通過具有成本效益和高效解決方案來提高推動醫療產品生產力。藥明康德連續第四年獲得了MSCI的AA ESG評級,並且其開放式平台讓來自30多個國家的6000多客戶改善急需人群的健康,並實現「每種藥物都可以製造,每種疾病都可以治療」的願景。
SOURCE WuXi AppTec
來源 藥明康德
譯文內容由第三人軟體翻譯。